Latest News-Deqi(Zhejiang)Pharmaceutical Technology Co. Ltd. Mediaroom_Page

Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022

SHANGHAI and HONG KONG, Sept. 21, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", ...

2026-09-21 08:30 1221

Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy

SHANGHAI and HONG KONG, Sept. 14, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene",...

2026-09-14 12:38 1887

Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases

SHANGHAI and HONG KONG, Aug. 25, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2026-08-25 08:30 1855

Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D

SHANGHAI and HONG KONG, Aug. 24, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2026-08-24 09:00 2961

Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit

SHANGHAI and HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2026-08-19 09:00 1698

Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026

SHANGHAI and HONG KONG, July 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2026-07-20 15:00 3180

Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB

SHANGHAI and HONG KONG, July 13, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2026-07-13 12:00 3590

Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE

* ATG-106 is a first-in-class CDH6 x CD3 bispecific T cell engager (TCE) in preclinical developm...

2026-06-22 08:30 7109

Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China

SHANGHAI and HONG KONG, June 10, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", ...

2026-06-10 09:00 6990

Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance

SHANGHAI and HONG KONG, June 8, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2026-06-08 08:00 7397

Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026

SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2026-06-03 12:00 9053

Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer

SHANGHAI and HONG KONG, May 28, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2026-05-28 08:00 5517

Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline

SHANGHAI and HONG KONG, May 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2026-05-20 08:00 6445

Antengene Presents Three Novel Programs at AACR 2026, Highlighting Next-Generation ADC and AnTenGager® TCEs

SHANGHAI and HONG KONG, April 18, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene",...

2026-04-18 08:30 7674

Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability

SHANGHAI and HONG KONG, March 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", ...

2026-03-20 17:14 9684

Antengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs

SHANGHAI and HONG KONG, March 18, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene",...

2026-03-18 08:30 6759

Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases

* Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-2...

2026-03-04 06:00 6622

XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication

- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health I...

2026-03-02 08:30 6521

Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)

SHANGHAI and HONG KONG, Feb. 25, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", ...

2026-02-25 08:30 5361

Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs

SHANGHAI and HONG KONG, Jan. 16, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2026-01-16 09:00 9472